Responsive exosome nano-bioconjugates for synergistic cancer therapy.
Exosomes hold great potential in therapeutic development. However, native exosomes usually induce insufficient effects in vivo, and simply act as drug delivery vehicles. Here, we report a chemical engineering approach to construct responsive exosome nano-bioconjugates for synergistic cancer therapy. Azide modified exosomes derived from M1 macrophages are conjugated with dibenzocyclooctynes modified antibodies of CD47 and SIRPα (aCD47 and aSIRPα) through pH-sensitive linker. After system administration, such exosome nanobioconjugates can actively target tumors through the specific recognition between aCD47 and CD47 on tumor cell surface. In the acidic tumor microenvironment, the benzoic-imine bonds of exosome nanobioconjugates are cleaved to release aSIRPα and aCD47 that can respectively block SIRPα on macrophages and CD47, leading to abolished "don't eat me" signaling and improved phagocytosis of macrophages. Meanwhile, the native M1 exosomes effectively transit the macrophages from pro-tumoral M2 to anti-tumoral M1 owing to their abundant contents for M2 reprogram. Thus, the exosome bioconjugates exert the synergistic anticancer effect.